Jim Healy

Jim Healy, Managing Partner and Chairman at Sofinnova Investments with decades in venture investing focused on therapeutics. He discusses product versus platform tradeoffs, why Sofinnova favors de-risked clinical-stage deals, how board seats and long holds shape outcomes, therapeutic and modality preferences, and how regulatory clarity and pharma interest drive diligence decisions.